
Please try another search
Ingevity Corporation (NYSE:NG) announced that its board approved an authorization to buy back up to $500 million of its outstanding common stock.
Additionally, the company plans to purchase up to $250 million in shares over the coming 12 to 18 months.
Notably, in view of the new authorization, its 2017 and 2018 stock repurchase plans have been rescinded.
Per management, prioritizing share buyback is warranted given the existing market conditions and its expectations for the company. Notably, the authorization gives Ingevity the flexibility to be opportunistic through 2020.
Shares of the company have lost 57.1% in the past year compared with the industry’s decline of 9.6%.
On the fourth-quarter earnings call, Ingevity expected sales of $1.3-$1.35 billion for 2020. It also anticipated adjusted EBITDA of $400-$420 million for the year.
Free cash flow for 2020 has been forecast to be $200-$220 million.
The company expects little to no improvement in the global macroeconomic climate but anticipates minimal impact (which is yet to be known) from the coronavirus outbreak in China.
It expects revenues to be flat to down modestly for the Performance Chemicals segment. Engineered polymers and pavement technologies are expected to witness solid growth, which is likely to be offset by ongoing pressure in industrial specialties and oilfield applications.
Ingevity also expects to generate double-digit revenue growth and accretion in adjusted EBITDA margins for the Performance Materials unit.
Ingevity Corporation Price and Consensus
Zacks Rank & Stocks to Consider
Ingevity currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the basic materials space are Daqo New Energy Corp. (NYSE:DQ) , NovaGold Resources Inc. (NYSE:NG) and Commercial Metals Company (NYSE:CMC) .
Daqo New Energy has a projected earnings growth rate of 353.7% for 2020. The company’s shares have rallied 70.7% in a year. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
NovaGold has a projected earnings growth rate of 11.1% for 2020. It currently carries a Zacks Rank #2 (Buy). The company’s shares have surged 117.2% in a year.
Commercial Metals currently has a Zacks Rank #2 and a projected earnings growth rate of 21.6% for 2020. The company’s shares have rallied 11.3% in a year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Tesla (NASDAQ:TSLA) (NYSE: TSLA), the electric vehicle giant, has recently experienced a significant drop in its stock value, which has fallen nearly 45% since December. This...
Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...
I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.